Premium
Frequency and severity of transfusion‐related acute lung injury – German haemovigilance data (2006–2007)
Author(s) -
KellerStanislawski B.,
Reil A.,
Günay S.,
Funk M. B.
Publication year - 2010
Publication title -
vox sanguinis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.68
H-Index - 83
eISSN - 1423-0410
pISSN - 0042-9007
DOI - 10.1111/j.1423-0410.2009.01232.x
Subject(s) - medicine , antibody , human leukocyte antigen , fresh frozen plasma , platelet , immunology , panel reactive antibody , pregnancy , immune system , gastroenterology , antigen , biology , genetics
Objective In an observational cohort study (2006–2007) the Paul‐Ehrlich‐Institut collected epidemiological data to investigate the frequency and causes of TRALI. Methods Diagnosis of TRALI was confirmed according to criteria of the European Haemovigilance Network. Subsequent testing of white blood cell antibodies (WBC‐Ab) against HLA or human neutrophil alloantigens was performed. Results Of a total of 187 reported TRALI cases, 44 could be confirmed consisting of 35 cases of antibody‐mediated TRALI and nine cases of non‐immune‐mediated TRALI. Eight of 44 affected patients (18%) had a fatal outcome, seven cases with WBC‐Ab positive plasma donors and one case with red blood cell donors. WBC antibodies were found in one male and 39 female donors. In 34 female donors, a history of pregnancy was confirmed. WBC‐Ab positive donors presented four HLA class I antibodies, 15 HLA class II antibodies, 13 HLA class I and class II antibodies, one HNA‐2a, and seven HNA‐3a antibodies. WBC antibodies matching with recipient antigens were found exclusively in 28 female donors; 26 FFP donors, one platelet donor and one red blood cell donor. Reporting frequency of immune‐mediated TRALI was 1 : 66 000 for fresh frozen plasma, 1 : 2.86 million for red blood cell concentrates and 1 : 420 000 for platelet concentrates. Reporting frequency of TRALI‐related fatalities was 1 : 285 000 for FFP. Summary Haemovigilance data show the significance of female donors with a history of pregnancy for the development of antibody‐mediated TRALI. Manufacturing of FFP from male plasma and female donor screening for WBC‐Ab could represent preventive measures.